Table 2.
Number of women assessed, Z-endoxifen level at study exit, and mammographic density at baseline, exit and, absolute difference in relation to dose of topical endoxifen.
| Characteristic | Dose group | |||
|---|---|---|---|---|
| Doses combined | 0 mg | 10 mg | 20 mg | |
| Plasma Z-endoxifen level, at exit | ||||
| No. of women assessed | 71 | 25 | 20 | 26 |
| Exit Z-endoxifen level (ng/mL), median (95% CIa) | <0.05 | 0.24 (0.10 to 0.49) | 0.75 (0.38 to 1.11) | |
| Mammographic density, at baseline and exit | ||||
| No. of women assessed at baseline/exit | 90/74 | 30/26 | 30/23 | 30/27 |
| Baseline mammographic density, mean (SDb) | 24.5 (16.0) | 23.6 (17.2) | 23.9 (12.9) | 26.2 (18.0) |
| Exit mammographic density, mean (SDb) | 22.4 (16.5) | 22.0 (17.8) | 22.4 (14.0) | 22.8 (18.0) |
| Absolute differencec, mean (95% CIa) | −2.2 (−3.4 to −0.9) | −1.6 (−3.6 to 0.3) | −1.5 (−3.5 to 0.6) | −3.4 (−6.7 to −0.6) |
95% confidence interval.
Standard deviation.
Absolute differences were calculated for women with available baseline and exit measures.